Current Report Filing (8-k)
13 February 2021 - 12:38AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 12, 2021
KINTARA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada
|
|
001-37823
|
|
99-0360497
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
12707 High Bluff Dr., Suite 200
San Diego, CA 92130
(Address of principal executive offices)
Registrants telephone number, including area code: (858) 350-4364
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
KTRA
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 Results of Operations and Financial Condition.
Kintara Therapeutics, Inc. (the Company) issued a press release on February 12, 2021, disclosing financial information and operating metrics for
the second quarter ended December 31, 2020, and providing a corporate update. A copy of the Companys press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
Item 7.01 Regulation FD Disclosure.
See Item 2.02 Results of Operation and Financial Condition above.
The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in
Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth
by a specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
KINTARA THERAPEUTICS, INC.
|
|
|
|
Date: February 12, 2021
|
|
By:
|
|
/s/ Scott Praill
|
|
|
|
|
Name: Scott Praill
Title: Chief Financial
Officer
|
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Apr 2024 to May 2024
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From May 2023 to May 2024